Neuroscience

Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder

Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain StimulationBURLINGTON, Mass. and JERUSALEM, Jan. 31, 2023...

Ring Therapeutics Announces Appointment of Industry Veteran Christopher Wright, M.D., Ph.D. as Chief Medical Officer, Head of Translational Research

CAMBRIDGE, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize...

Precision Neuroscience Raises $41 Million to Build and Scale the Next Generation of Treatments for Neurological Illnesses

The brain–computer interface company advances the industry with plans for a minimally invasive, reversible implant.NEW YORK, Jan. 25, 2023 (GLOBE...

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...

BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate Cancer

Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at...

AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million

IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”), a clinical-stage biopharmaceutical company focused...

error: Content is protected !!